The results of longterm therapy with the oral gold preparation @entity2044 in @entity1 with @entity309 ( @entity309 ) were evaluated based on the following data: 1) Two multicenter open uncontrolled studies (MTC06) and (162EMUA- @entity309 ), 2) the reevaluation of these data for the MTC06 study after 4 years from the beginning of the study and 3) the results of a postmarketing surveillance program (PMSP) of @entity1 on @entity2044 therapy. The specific rheumatologic documentation and information system (IKR inhaltkodierte rheumatologic) serves as the basis of the follow-up studies and longterm observations. The first year data on 207 @entity1 (MTC06) indicating that duration of the disease less than 2 years was the only discriminating factor regarding a positive treatment outcome were confirmed by the two-year (151 @entity1 ). @entity1 , who responded favourably to @entity2044 did usually well for the four-year or longer observation period. The data base of these two studies and the PMSP failed to outline any new severe or threatening side effects. @entity294 and loose stools were more common at the beginning of the treatment. The overall withdrawal for untoward events was 11.2%. @entity1 who did or did not respond to previous DIMARD therapy either on i.m. gold, @entity2361 or @entity503 , did usually well when treated with @entity2044 , even if severe side effects leading to withdrawal had occurred on previous therapy. The favourable safety profile was confirmed by the PMSP data.

Longterm results of XXXX therapy.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity294 :: ('MESH:D003967', 'Disease') :: ['Diarrhea'] @entity2361 :: ('MESH:D010396', 'Chemical') :: ['D-Penicillamine'] @entity503 :: ('MESH:D002738', 'Chemical') :: ['Chloroquine'] @entity309 :: ('MESH:D001172', 'Disease') :: ['rheumatoid arthritis', 'RA'] @entity2044 :: ('MESH:D001310', 'Chemical') :: ['Auranofin', 'auranofin']
@entity2044 :: (MESH:D001310,Chemical) :: ['auranofin']
